The relationship between EGFR variant allele frequency and efficacy of Osimertinib in EGFR mutation-positive NSCLC

Seigo Katakura

Presentation information

Mini-Oral Session

[MO29] Mini-Oral Session 29　Lung Cancer / Thoracic Cancer 4（EGFR-TKI 1）
【E】

Fri. Feb 18, 2022 9:55 AM - 10:45 AM Room 13 (Gold Room, B2F, The Prince Kyoto Takaragaike)

Chair：Kazuma Kishi（Department of Respiratory Medicine, Toho University），Toshiyuki Kozuki（Clinical Research Center, National Hospital Organization Shikoku Cancer Center）

[MO29-1] The relationship between EGFR variant allele frequency and efficacy of Osimertinib in EGFR mutation-positive NSCLC

^○Seigo Katakura¹, Shuji Murakami¹, Shinada Kanako¹, Ushio Ryota¹, Kondo Tetsuro¹, Kato Terufumi¹, Yokose Tomoyuki², Saito Haruhiro¹ (1.Department of Thoracic Oncology, Kanagawa Cancer Center, 2.Department of Pathology, Kanagawa Cancer Center)

Abstract password authentication.
The password can be found on page 27 of the program book.

Presentation information

[MO29] Mini-Oral Session 29 Lung Cancer / Thoracic Cancer 4（EGFR-TKI 1）【E】

[MO29-1] The relationship between EGFR variant allele frequency and efficacy of Osimertinib in EGFR mutation-positive NSCLC

Password

[MO29] Mini-Oral Session 29　Lung Cancer / Thoracic Cancer 4（EGFR-TKI 1）
【E】